National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.

NCPE Rapid Review Process Complete
Rapid Review  Comissioned 08/08/2017
Rapid Review Completed 09/10/2017
Outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 11/10/2017
Pre-submission consultation with Applicant 28/11/2017
Submission received from Applicant 08/01/2018
Preliminary review sent to Applicant 29/05/2018
NCPE assessment re-commenced 15/06/2018
Preliminary review II sent to Applicant 31/07/2018
NCPE assessment re-commenced 21/08/2018
Factual accuracy sent to Applicant 04/09/2018
NCPE assessment re-commenced 19/09/2018
NCPE assessment completed 20/09/2018
NCPE assessment outcome The NCPE recommends that atezolizumab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary